ArticleThe international journal of neuropsychopharmacology2010
Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.
Article in The international journal of neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Observational
- Genetic polymorphism in HTR2A rs6313 is associated with internet addiction disorder.Frontiers in psychiatry · 2024Article
- Genetic contributions to brain serotonin transporter levels in healthy adults.Scientific reports · 2023Article
- DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs.Biomedicines · 2023Article
- Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder.The pharmacogenomics journal · 2021Review
- Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels.Human brain mapping · 2020Article
- Gene-Based Association Analysis Suggests Association ofFrontiers in pharmacology · 2020Article
- Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.Neuropsychiatric disease and treatment · 2018Article
- Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.The pharmacogenomics journal · 2016Article
- 5-HT2A Gene Variants Moderate the Association between PTSD and Reduced Default Mode Network Connectivity.Frontiers in neuroscience · 2016Article
- 5-HTTLPR, HTR1A, and HTR2A cumulative genetic score interacts with mood reactivity to predict mood-congruent gaze bias.Cognitive, affective & behavioral neuroscience · 2014Article
- Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems.Human brain mapping · 2014Article
- Race, genetic ancestry and response to antidepressant treatment for major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.Psychiatry research · 2013Article
- Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.Frontiers in psychiatry · 2013Article
- Genome-wide association studies of antidepressant outcome: a brief review.Progress in neuro-psychopharmacology & biological psychiatry · 2011Review
- Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.Molecular psychiatry · 2011Article
- Biomarkers to predict antidepressant response.Current psychiatry reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
In a previous study we showed that genetic variation in HTR2A, which encodes the serotonin 2A receptor, influenced outcome of citalopram treatment in patients with major depressive disorder. Since chronic administration of citalopram, which selectively and potently inhibits the serotonin transporter (5-HTT), putatively enhances serotonergic transmission, it is conceivable that genetic variation within HTR2A also influences pretreatment 5-HTT function or serotonergic transmission. The present study used positron emission tomography (PET) and the selective 5-HTT ligand, [11C]DASB, to investigate whether the HTR2A marker alleles that predict treatment outcome also predict differences in 5-HTT binding. Brain levels of 5-HTT were assessed in vivo using PET measures of the non-displaceable component of the [11C]DASB binding potential (BPND). DNA from 43 patients and healthy volunteers, all unmedicated, was genotyped with 14 single nucleotide polymorphisms located within or around HTR2A. Allelic association with BPND was assessed in eight brain regions, with covariates to control for race and ethnicity. We detected allelic association between [11C]DASB BPND in thalamus and three markers in a region spanning the 3' untranslated region and second intron of HTR2A (rs7333412, p=0.000045; rs7997012, p=0.000086; rs977003, p=0.000069). The association signal at rs7333412 remained significant (p<0.05) after applying corrections for multiple testing via permutation. Genetic variation in HTR2A that was previously associated with citalopram treatment outcome was also associated with thalamic 5-HTT binding. While further work is needed to identify the actual functional genetic variants involved, these results suggest that a relationship exists between genetic variation in HTR2A and either 5-HTT expression or central serotonergic transmission that influences the therapeutic response to 5-HTT inhibition in major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.